Advertisement

Prognostic Factors in Non-Small Cell Lung Cancer

  • M. I. Quejada
  • K. S. Albain

Abstract

The TNM staging classification is the strongest determinate of outcome in patients with non-small cell lung cancer (NSCLC); as a result, it is used to guide treatment decisions (see Chap. 16). Only those patients who undergo complete resection or are treated aggressively with combined modality therapy have the potential for long-term survival. However, even with stage IA tumors, the 5-year survival rate after resection is only 67% (Mountain 1997; Kwiatkowski et al. 1998), indicating that a significant proportion of patients with resectable disease have virulent tumors. The range of survival potentials within each stage underscores the heterogeneous nature of the disease. This has led to the study of other prognostic variables that might complement stage, and to a search for tissue-based, as well as noninvasive, methods for better predicting prognosis and guiding treatment choice (Pugsley et al. 2002; Sorensen 1994).By refining the prognostic assessment of a given patient within (or potentially across) stage subgroups, a better tailored therapy might be feasible.

Keywords

Lung Cancer Cell Lung Cancer Proliferate Cell Nuclear Antigen Small Cell Lung Cancer Small Cell Lung Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahuja V, Coleman RE, Herndon J et al (1998) The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer 83:918PubMedCrossRefGoogle Scholar
  2. Aisner J, Hansen HH (1981) Commentary: current status if chemotherapy for NSCLC. Cancer Treat Rep 65: 979PubMedGoogle Scholar
  3. Alama A, Constantini M, Repetto L et al (1990) Thymidine labeling index as prognostic factor in resected non-small cell lung cancer. Eur J Cancer 26:622PubMedCrossRefGoogle Scholar
  4. Albain KS, Crowley JJ, LeBlanc M et al (1991) Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9:1618PubMedGoogle Scholar
  5. Al-Kattan K, Sepsas E, Townsend E et al (1996) Factors affecting long-term survival following resection for lung cancer. Thorax 51:1266PubMedCrossRefGoogle Scholar
  6. Andre F, Grunenwald D, Pignon JP et al (2000) Survival of patients with resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18:2981PubMedGoogle Scholar
  7. Apolinario RM, van der Valk P, de Jong JS et al (1997) Prognostic value of the expression of p53, bcl-2 and bax oncoproteins and neovascularization in patients with radically resected nonsmall cell lung cancer. J Clin Oncol 15:2456PubMedGoogle Scholar
  8. Battifora H, Sorensen HR, Mehta P et al (1992) Tumor-associated antigen 43-9F is of prognostic value in squamous cell carcinoma of the lung. Cancer 70:1867PubMedCrossRefGoogle Scholar
  9. Berendsen HH, de Leij L, Poppema S et al (1989) Clinical characterization of non-small cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 7:1614PubMedGoogle Scholar
  10. Bernet F, Brodbeck R, Guenin MO et al (2000) Age does not influence early and late tumor-related outcome for bronchogenic carcinoma. Ann Thorac Surg 69:913PubMedCrossRefGoogle Scholar
  11. Blackstock AW, Herndon JE 2nd, Paskett ED et al (2002) 0utcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst 94:284PubMedCrossRefGoogle Scholar
  12. Bonomi P (2002) Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 29 [Suppl 4]:78PubMedCrossRefGoogle Scholar
  13. Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG Performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A:1135PubMedCrossRefGoogle Scholar
  14. Carbone DP, Mitsudomi T, Chiba I et al (1994) p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 106 [Suppl6]:377SPubMedGoogle Scholar
  15. Cattoretti G, Becker MH, Key G et al (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357PubMedCrossRefGoogle Scholar
  16. Chen CY, Hsu CP, Hsu NY et al (2002) Expression of dihydrodiol dehydrogenase in the resected stage I non-small cell lung cancer. Oncol Rep 9:515PubMedGoogle Scholar
  17. Chiba I, Takahashi T, Nau MM et al (1990) Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603PubMedGoogle Scholar
  18. Cho JY, Kim JH, Lee YH et al (1997) Correlation between K-ras gene mutation and prognosis of patients with non-small cell lung carcinoma. Cancer 79:462PubMedCrossRefGoogle Scholar
  19. Choma D, Daures JP, Quantin X et al (2001) Aneuploidy and prognosis of non-small cell lung cancer: a meta-analysis of published data. Br J Cancer 85:14PubMedCrossRefGoogle Scholar
  20. Cote RJ, Beattie EJ, Chaiwun B et al (1995) Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 222:415PubMedGoogle Scholar
  21. D’Amico TA, Massey M, Herndon JE 2nd et al (1999) A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117:736PubMedCrossRefGoogle Scholar
  22. Deslaurier J, Brisson J, Cartier R et al (1989) Carcinoma of the lung. Evaluation of satellite nodules as a factor in influencing prognosis after resection. J Thorac Cardiovasc Surg 97:504Google Scholar
  23. Dhital K, Saunders CA, Seed PT et al (2000) [(l8)F] Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 18:425PubMedCrossRefGoogle Scholar
  24. Dresler CN, Ritter JH, Wick MR et al (1995) Immunostains for blood group antigens lack prognostic significance in T1 lung carcinomas. Ann Thorac Surg 59:1069PubMedCrossRefGoogle Scholar
  25. Duarte I, Buflin BL, Pennington MF et al (1998) Angiogenesis as a predictor of survival after surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 115:652PubMedCrossRefGoogle Scholar
  26. Duhaylungsod FG, Lowe VJ, Patz EF et al (1995) Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60:1348CrossRefGoogle Scholar
  27. Ebina M, Steinberg SM, Mulshine JL et al (1994) Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54:2496PubMedGoogle Scholar
  28. Feinstein AR (1964) Symptomatic patterns, biologic behavior and prognosis in cancer of the lung. Ann Intern Med 61:27PubMedGoogle Scholar
  29. Feld R, Abratt R, Graziano S et al (1997) Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer 17 [Suppl 1]:S3PubMedCrossRefGoogle Scholar
  30. Feld R, Borges M, Giner V et al (1994) Prognostic factors in non-small cell lung cancer. Lung Cancer 11 [Suppl 3]:S19PubMedCrossRefGoogle Scholar
  31. Ferguson MK, Skosey C, Hoffman PC et al (1990) Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 8:1402PubMedGoogle Scholar
  32. Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986) Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 4:702PubMedGoogle Scholar
  33. Fontanini G, DeLaurentiis M, Vignati S et al (1998) Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small cell lung cancer:amphiregulin and microvessel count are independent indicators of survival. Clin Cancer Res 4:241PubMedGoogle Scholar
  34. Fontanini G, Lucchi M, Vignati S et al (1997) Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 89:881PubMedCrossRefGoogle Scholar
  35. Fontanini G, Vignati S, Bigini JD et al (1995) BCL-2 protein: a prognostic factor inversely correlated to p53 in non-small cell lung cancer. Br J Cancer 71:1003PubMedCrossRefGoogle Scholar
  36. Fujii M, Motoi M, Saeki H et al (1993) Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in non-small cell lung cancer. Acta Med Okayama 47:103PubMedGoogle Scholar
  37. Gaffney EF, O’Neil AJ, Staunton MJ (1994) bcl-2 and prognosis in non-small-cell lung carcinoma. N Engl J Med 330:1757PubMedCrossRefGoogle Scholar
  38. Gail M, Eagan RT, Feld R et al (1984) Prognostic factors in patients with resected stage I NSCLC: a report from the Lung Cancer Study Group. Cancer 54:1802PubMedCrossRefGoogle Scholar
  39. Gerdes J, Lemke H, Baisch H et al (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710PubMedGoogle Scholar
  40. Giatromanolaki A, Gorgiulis V, Chetty R et al (1996) C-ERB B-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res 16:987PubMedGoogle Scholar
  41. Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 NO non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615CrossRefGoogle Scholar
  42. Graziano SL (1997) Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 17 [Suppl 1]:S37PubMedCrossRefGoogle Scholar
  43. Graziano SL, Mazid R, Newman N et al (1989) The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small cell lung cancer. J Clin Oncol 7:1398PubMedGoogle Scholar
  44. Graziano SL, Tatum AH, Newman NB et al (1994) The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res 54:2908PubMedGoogle Scholar
  45. Graziano SL, Gamble GP, Newman NB et al (1999) The prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small cell lung cancer. I Clin Oncol 17:668Google Scholar
  46. Greatens TM, Niehans GA, Rubins JB et al (1998) Do molecular markers predict survival in non-small cell lung cancer? Am J Respir Crit Care Med 157:1093PubMedCrossRefGoogle Scholar
  47. Gwin JL, Klein-Szanto AJ, Zhang SY et al (1994) Loss of blood group antigen A in non-small cell lung cancer. Ann Surg Oncol 1:423PubMedCrossRefGoogle Scholar
  48. Harada M, Dosaka-Akita H, Miyamoto H et al (1992) Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 69:72–77PubMedCrossRefGoogle Scholar
  49. Harpole DH (1999) Commentary on “Prognostic markers in resected stage I and II non-small cell lung cancer patients”. Clin Lung Cancer 1:68CrossRefGoogle Scholar
  50. Harpole DH, Herndone JE, Young WG et al (l995a) Stage I non-small cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. Cancer 76:787CrossRefGoogle Scholar
  51. Harpole DH, Herndon JE, Wolfe WG et al (l995b) A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Res 55:51Google Scholar
  52. Harpole DH, Richards WG, Herndon JE et al (1996) Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 61:1470PubMedCrossRefGoogle Scholar
  53. Higashi K, Veda y, Ayabe K et al (2000) FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 21: 707PubMedCrossRefGoogle Scholar
  54. Hommura F, Dosaka-Akita H, Mishina T et al (1999) Prognostic significance of p27KIPI protein and ki-67 growth fraction in non-small cell lung cancer. Lung Cancer 24:81CrossRefGoogle Scholar
  55. Hsu NY, Ho HC, Chow KC et al (2001) Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 61:2727PubMedGoogle Scholar
  56. Icard P, Regnard JF, Essomba A et al (1994) Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer. Ann Thorac Surg 58:811PubMedCrossRefGoogle Scholar
  57. Ichinose Y, Yano T, Asoh H et al (1995) Prognostic factors obtained by a pathologic examination in completely resected non-small cell lung cancer. J Thorac Cardiovasc Surg 110:601PubMedCrossRefGoogle Scholar
  58. Inoue T, Ishida T, Sugio K et al (1994) Cathepsin B expression and laminin degradation as factors influencing prognosis of surgically treated patients with lung adenocarcinoma. Cancer Res 54:6133PubMedGoogle Scholar
  59. Ishida T, Kaneko S, Akazawa K et al (1993) Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients. Cancer Res 53:5000PubMedGoogle Scholar
  60. Isobe H, Miyamoto H, Shimizu T et al (1990) Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer 65:1391PubMedCrossRefGoogle Scholar
  61. Izbicki JR, Passlick, Hosch SB et al (1996) Mode of spread in the early phase of lymphatic metastasis in non-small cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg 112:623PubMedCrossRefGoogle Scholar
  62. Izumi M, Nakanishi Y, Yoshino I et al (2001) Expression of tumorassociated antigen RCASI correlates significantly with poor prognosis in non-small cell lung carcinoma. Cancer 92:446PubMedCrossRefGoogle Scholar
  63. Jansen RL, Hupperets PS, Arends JW et al (1998) MIB-1 labeling index is an independent prognostic marker in primary breast cancer. Br J Cancer 78:460PubMedCrossRefGoogle Scholar
  64. Jazieh AR, Hussain Mohammad, Howington JA et al (2000) Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. Ann Thorac Surg 70:1168PubMedCrossRefGoogle Scholar
  65. Kaneko S, Ishida T, Sugio K et al (1991) Nucleolar organizer regions as a prognostic indicator for stage I non-small cell lung cancer. Cancer Res 51:4008PubMedGoogle Scholar
  66. Kern JA, Schwartz DA, Nordberg JE et al (1990) p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184–5187PubMedGoogle Scholar
  67. Kessler R, Gasser B, Massard G et al (1996) Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer. Ann Thorac Surg 62:1489PubMedCrossRefGoogle Scholar
  68. Kimura Y, Fujii T, Hamamoto K et al (1990) Serum CA 125 level is a good prognostic indicator in lung cancer. Br J Cancer 62:676PubMedCrossRefGoogle Scholar
  69. Klatersky J, Sculier IP, Bureau G et al (1989) Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 7:1087Google Scholar
  70. Komaki R, Milas L, Ro JY et al (1998) Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer. Int J Radiat Oncol Biol Phys 40:787PubMedCrossRefGoogle Scholar
  71. Kos J, Sekirnik A, Kopitar G, Cimerman N et al (2001) Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Br J Cancer 85:1193PubMedCrossRefGoogle Scholar
  72. Kubuschok B, Passlick B, Izbicki JR et al (1999) Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 17:19PubMedGoogle Scholar
  73. Kwiatkowski DJ Jr, DHH, Godleski J et al (1998) Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients: clinical implications. J Clin Oncol 16:2468PubMedGoogle Scholar
  74. Lanzotti VJ, Thomas DR, Boyle LE et al (1977) Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria. Cancer 39:303PubMedCrossRefGoogle Scholar
  75. Lee JS, Ro JY, Sahin AA et al (1991) Expression of blood-group antigen A: a favorable prognostic factor in non-small cell lung cancer. N Engl J Med 324:1084PubMedCrossRefGoogle Scholar
  76. Linnoila RI, Jensen S, Steinberg S et al (1989) Neuroendocrine differentiation in non-small cell lung cancer correlates with favorable response to chemotherapy. Proc Am Soc 8:248Google Scholar
  77. Linnoila RI, Piantadosi S, Ruckdeschel JC (1994) Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest 106:367SPubMedGoogle Scholar
  78. Lipford EH III, Ehhleston JC, Lillemoe KD et al (1984) Prognostic factors in surgically resected limited stage non-small cell carcinoma of the lung. Am J Surg Pathol 8:357PubMedCrossRefGoogle Scholar
  79. Little AG, Wu HS, Ferguson MK et al (1990) Perioperative blood transfusion adversely affects prognosis of patients with stage I non-small-cell lung cancer. Am J Surg 160:630PubMedCrossRefGoogle Scholar
  80. Luedke DW, Einhorn L, Omura GA et al (1990) Randomized comparison of two combination regimens versus minimal chemotherapy in non-small cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol 8:886PubMedGoogle Scholar
  81. Macchiarini P, Fontanini GM, Hardin MJ et al (1992) Relation of neovascul arization to metastasis of non-small cell lung cancer. Lancet 340:145PubMedCrossRefGoogle Scholar
  82. Macchiarini P, Fontanini G, Hardin MJ et al (1993) Blood vessel invasion by tumor cells predicts recurrence in completely resected TlNOMO non-small cell lung cancer. J Thorac Cardiovase Surg 106:80Google Scholar
  83. Maggi G, Casadio C, Cianci R et al (1993) Results of surgical resection of stage IIIa (N2) non small cell lung cancer, according to the site of the mediastinal metastases. Int Surg 78:213PubMedGoogle Scholar
  84. Mankoff DA, Shields AF, Graham MM et al (1998) Kinetic analysis of 2-[carbo-ll) thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med 39:1043PubMedGoogle Scholar
  85. Martini N, Bains MS, Burt ME et al (1995) Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109:120PubMedCrossRefGoogle Scholar
  86. Martini N, Burt M, Bains M et al (1992) Survival after resection of stage II non-small cell lung cancer. Ann Thorac Surg 54:460PubMedCrossRefGoogle Scholar
  87. Matsumoto H, Muramatsu H, Shimotakahara T et al (1993) Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas. Cancer 72:75PubMedCrossRefGoogle Scholar
  88. McLaren R, Kuzu I, Dunnill M et al (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735PubMedCrossRefGoogle Scholar
  89. Mehdi SA, Tatum AH, Newman NB et al (1999) Prognostic markers in resected stage I and II non-small cell lung cancer: an analysiss of 260 patients with 5 year follow-up. Clin Lung Cancer 1:59PubMedCrossRefGoogle Scholar
  90. Miller TP, Chen TT, Coltman Ca et al (1986) Effect of alternating combination chemotherapy on survival of ambulatory patient s with metastatic large cell and adenocarcinoma of the lung. A Southwest Oncology Group Study. J Clin Oncol 4:502PubMedGoogle Scholar
  91. Mitsudomi T, Steiberg SM, Oie H et al (1991) Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51:4999PubMedGoogle Scholar
  92. Mitsudomi T, Steinberg SM, Nau MM et al (1992) p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171PubMedGoogle Scholar
  93. Mitsudomi T, Hamajima N, Ogawa M et al (2000) Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6:4055PubMedGoogle Scholar
  94. Miyake M, Taki T, Hitomi S et al (1992) Correlation of expression of H/Ley/Leb antigens with survival in patients with carcinoma of the lung. N Engl J Med 327:14PubMedCrossRefGoogle Scholar
  95. Mizushima Y, Noto H, Sugiyama S et al (1997) Survival after pneumonectomy for lung patients in the elderly. Ann Thorac Surg 64:93CrossRefGoogle Scholar
  96. Molino A, Micciolo R, Turazza M et al (1997) Ki-67 immunostaining in 322 primary breast cancers:associations with clinical and pathological variables and prognosis. Int J Cancer 74:433PubMedCrossRefGoogle Scholar
  97. Mori M, Kohli A, Baker SP et al (1997) Laminin and cathepsin Bas a prognostic factor in stage I non-small cell lung cancer: are they useful? Modern Pathol 10:572Google Scholar
  98. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710PubMedCrossRefGoogle Scholar
  99. Murgueza JM, Diez M, Torres AJ et al (1997) Prognostic value of flow cytometric DNA analysis in non-small cell lung cancer: rationales of sequential processing of frozen and paraffin-embedded tissue. World J Surg 21:323CrossRefGoogle Scholar
  100. Nabeshima K, Shimao Y, Inoue T et al (2002) Matrix metalloproteinases (MMP) in lung cancer. Nippon Rinsho 60 [Suppl 5]: 103PubMedGoogle Scholar
  101. Naito T, Satoh H, Ishikawa H et al (1997) Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res 17:4743PubMedGoogle Scholar
  102. Naruke T, Tsuchiya R, Kondo H et al (2001) Prognosis and survival for bronchogenic carcinoma based on the 1997 TNM staging classification: the Japanese experience. Ann Thorac Surg 71:1759PubMedCrossRefGoogle Scholar
  103. O’Connell JP, Kris MG, Gralla RJ et al (1986) Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 4:1604PubMedGoogle Scholar
  104. Ohgami A, Tetsuya M, Kenji S et al (1997) Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer without overt meta stases. Lancet 64:363Google Scholar
  105. Ohsaki Y, Toyoshima E, Fujiuchi S et al (1996) p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res 2:915PubMedGoogle Scholar
  106. Okada M, Tsubota N, Yoshimura M et al (1999) Evaluation of TNM classification for lung carcinoma with ipsilateral intrapulmonary metastasis. Ann Thorac Surg 68:326PubMedCrossRefGoogle Scholar
  107. Oyama T, Mitsudomi T, Yoshida Y et al (1993) Nucleolar organizer regions are independently associated with a shortened survival in patients with non-small cell lung cancer. Surg Oncol 6:341CrossRefGoogle Scholar
  108. Padilla J, Calvo V, Penalver JC et al (1997) Surgical results and prognostic factors in early non-small cell lung cancer. Ann Thorac Surg 63:324PubMedCrossRefGoogle Scholar
  109. Paesmans M, Sculier JP, Libert P et al (1995) Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1502 patients. J Clin Oncol 13:1221PubMedGoogle Scholar
  110. Pairolero PC, William DE, Bergstralh EJ et al (1984) Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 38:412CrossRefGoogle Scholar
  111. Palomares MR, Sayre JW, Shekar KC et al (1996) Gender influence on weight loss pattern and survival of non-small cell lung carcinoma patients. Cancer 78:2119PubMedCrossRefGoogle Scholar
  112. Pantel K, Izbicki J, Passlick B et al (1996) Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347:649PubMedCrossRefGoogle Scholar
  113. Pantel K, Passlick B, Vogt J et al (1998) Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small cell lung cancer. J Clin Oncol 16:1407PubMedGoogle Scholar
  114. Passlick B, Izbicki JR, Kubuschok B (1994) Immunohistochemical assessment of individual tumor cells in the lymph nodes of patients with non-small cell lung cancer. J Clin Oncol 12:1827PubMedGoogle Scholar
  115. Pastorino U, Andreola S, Tagliabue E et al (1977) Immunohistochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15:2858Google Scholar
  116. Pastorino U, Andreola S, Tagliabue E et al (1997) Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15:2858PubMedGoogle Scholar
  117. Pastorino U, Valente M, Cataldo I (1986) Perioperative blood transfusion and prognosis of resected stage Ia lung cancer. Eur J Cancer Clin Oncol 22:1375PubMedCrossRefGoogle Scholar
  118. Pelletier MP, Edwardes MD, Michel RP et al (2001) Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg 44:180PubMedGoogle Scholar
  119. Pena CM, Rice TW, Ahmad M et al (1992) Significance of perioperative blood transfusions in patients undergoing resection of stage I and II non-small-cell lung cancers. Chest 102:84PubMedCrossRefGoogle Scholar
  120. Pence JC, Kerns BM, Dodge RK et al (1993) Prognostic significance of the proliferation index in surgically resected non-small cell lung cancer. Arch Surg 128:1382PubMedCrossRefGoogle Scholar
  121. Pezzella F, Turley H, Kuzu I et al (1993) Bcl-2 protein in non-small lung carcinoma. N Engl J Med 329:690PubMedCrossRefGoogle Scholar
  122. Piantadosi S, Moores DW, McKneally MF (1994) The adverse effect of perioperative blood transfusion in lung cancer. Chest 106 [Suppl6]:382SPubMedCrossRefGoogle Scholar
  123. Poncelet AJ, Weynand B, Ferdin F (2001) Bone marrow micrornetastas is might not be a short-term predictor of survival in early stages non-small cell lung carcinoma. Eur J Cardio Thorac Surg 20:481CrossRefGoogle Scholar
  124. Puglisi F, Aprile G, Bruckbauer M et al (2001) Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas. Cancer Lett 162:97PubMedCrossRefGoogle Scholar
  125. Pugsley JM, Schmidt RA, Vesselle H et al (2002) The Ki-67 Index and Survival in non-small cell lung cancer: a review and relevance to positron emission tomography. Cancer J 8:222PubMedCrossRefGoogle Scholar
  126. Quinlan DC, Davidson AG, Summers CL et al (1992) Accumulation of p53 protein correlation with a poor prognosis in human lung cancer. Cancer Res 52:4828PubMedGoogle Scholar
  127. Rainio P, Bloigu R, Satta J et al (1996) Ten-year survival after resection for lung carcinoma. Effect of blood transfusion and tumour stage on outcome. Scand J Thorac Cardiovasc Surg 30:87PubMedCrossRefGoogle Scholar
  128. Rapp E, Pater JL, Willan A et al (1988) Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer — report of a Canadian multicenter randomized trial. J Clin Onco1 6:633Google Scholar
  129. Read RC, Schaefer R, North N et al (1988) Diameter, cell type and survival in stage I primary non-small cell lung cancer. Arch Surg 123:446PubMedCrossRefGoogle Scholar
  130. Read RC, Yoder G, Schaeffer RC (1990) Survival after conservative resection for T1 NO MO non-small cell lung cancer. Ann Thorae Surg 49:391CrossRefGoogle Scholar
  131. Rice TW, Tubbs RR, Hoeltge GA et al (1995) Expression of blood group ant igen A by stage I non-small cell lung carcinomas. Ann Thorac Surg 59:568PubMedCrossRefGoogle Scholar
  132. Ries LA (1994) Influence of extent of disease, histology and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol 10:21PubMedCrossRefGoogle Scholar
  133. Riquet M, Manac′h D, Le Pimpec B (1997) Prognostic value of T and N in non small cell lung cancer three centimeters or less in diameter. Eur J Cardiothorac Surg 11:440PubMedCrossRefGoogle Scholar
  134. Rodenhuis S, Slebos RJ (1992) Clinical significance of ras oncogene activation in human lung cancer. Cancer Res [Suppl] 52: 2665Google Scholar
  135. Rodenhuis S, Boerrigter L, Top B et al (1997) Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Onco1 15:285Google Scholar
  136. Rodrigues OR, Antonangelo L, Yagin et al (1997) Prognostic significance of argyrophilic nucleolar organizer region (AgNOR) in resected non-small cell lung cancer (NSCLC). Jpn J Clin Oncol 27:298PubMedCrossRefGoogle Scholar
  137. Rorke S, Murphy S, Khalifa M et al (2001) Prognostic significance of BAG-I expression in non-small cell lung cancer. Int J Cancer 95:317PubMedCrossRefGoogle Scholar
  138. Rosell R, Li S, Mate JL et al (1993) A prognostic impact of mutated k-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 8:2407PubMedGoogle Scholar
  139. Rubins JB, Dunitz J, Rubins HB et al (1998) Serum carcinoernbryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg 116:412PubMedCrossRefGoogle Scholar
  140. Rusch VW, Dmitrovsky E (1995) Molecular biologic features of non-small cell lung cancer: clinical implications. Chest Surg Clin North Am 5:39Google Scholar
  141. Sahin AA, Ro JY, El-Naggar AK et al (1990) Flow cytometric analysis of the DNA content of non-small cell lung cancer. Cancer 65:530PubMedCrossRefGoogle Scholar
  142. Salgia R, Skarin AT (1998) Molecular abnormalities in lung cancer. JCO 16:1207Google Scholar
  143. Schiller JH, Adak S, Feins R et al (1999) Prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer:preliminary results from a prospective randomized trial of postoperative adjuvant therapy (Intergroup Trial 0115). Proc Am Soc Clin Oncol 18:464a (abstract 1789)Google Scholar
  144. Segawa Y, Okahara M et al (1996) Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 15:67PubMedCrossRefGoogle Scholar
  145. Shiba M, Kohno H, Kakizawa K et al (2000) Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected non-small cell lung carcinoma. Cancer 89:1457PubMedCrossRefGoogle Scholar
  146. Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferat ion in vivo with [F-18] FLT and positron emission tomography. Nat Med 4:1334PubMedCrossRefGoogle Scholar
  147. Shields TW (1983) Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung. Surg Gynecol Obstet 157:185PubMedGoogle Scholar
  148. Slebos RJ, Kibbelaar RE, Dalesio O et al (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561PubMedCrossRefGoogle Scholar
  149. Sorensen JB (1994) Impact of prognostics factors on endpoints for clinical studies. Lung Cancer 11 [Suppl 3]:S45PubMedCrossRefGoogle Scholar
  150. Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25PubMedGoogle Scholar
  151. Staruss GM (1997) Prognostic markers in respectable non-small cell lung cancer. Hematol/Oncol Clin North Am 1:409CrossRefGoogle Scholar
  152. Stevenson H, Gazdar AF, Phelps R (1990) Tumor cell lines established in vitro: an independent prognostic factor for survival in non-small cell lung cancer. Ann Intern Med 113:764PubMedGoogle Scholar
  153. Sugio K, Ishida T, Yokoyama H et al (1992) Ras gene mutations as a prognostic marker in adenocarcinoma of the lung without lymph node metastasis. Cancer Res 52:2903PubMedGoogle Scholar
  154. Sugio K, Tsukamoto S, Ushijima C et al (2001) Clinical significance of the Rb expression in adenocarcinoma of the lung. Anticancer Res 21:1931PubMedGoogle Scholar
  155. Sukoh N, Abe S, Ogura S et al (1994) Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer. Cancer 74:46PubMedCrossRefGoogle Scholar
  156. Sulzer MA, Leers MPG, Noord JAV et al (1998) Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavourable prognosis in non-small cell lung cancer. Am J Crit Care Med 157:1319CrossRefGoogle Scholar
  157. Suzuki K, Nagai K, Yoshida J et al (1999) Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 67:927PubMedCrossRefGoogle Scholar
  158. Takise A, Kodama T, Shimosata Y et al (1988) Histopathologic prognostic factors in adenocarcinoma of the peripheral lung less than 2 em in diameter. Cancer 61:2083PubMedCrossRefGoogle Scholar
  159. Tanaka F, Miyahara R, Ohtake Y et al (1998) Lewis Y antigen expression and postoperative survival in non-small cell lung cancer. Ann Thorac Surg 157:1093Google Scholar
  160. Tartter PI, Burrows L, Kirschner P (1984) Perioperative blood transfusion adversely affects prognosis after resection of Stage I (subset NO) non-oat cell lung cancer. J Thorac Cardiovase Surg 88:659Google Scholar
  161. Tateishi M, Ishida T, Mitsudomi T et al (1991) Prognostic value of c-erbB-2 protein overexpression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27:1372PubMedCrossRefGoogle Scholar
  162. TenVelde GP, Havenith MG, Volovics A et al (1991) Prognostic significance of basement membrane deposition in operable squamous cell carcinomas of the lung. Cancer 67:3001CrossRefGoogle Scholar
  163. Thomas P, Doddoli C, Thirion X et al (2002) Stage I non-small cell lung cancer: a pragmatic approach to prognosis after complete resection. Ann Thorac Surg 73:1065PubMedCrossRefGoogle Scholar
  164. Thomas PA, Piantadosi S (1987) Postoperative T1N0 non-small cell lung cancer: squamous versus nonsquamous recurrences. J Thorac Cardiovasc Surg 94:349Google Scholar
  165. Tisi E, Lissoni P, Angeli M et al (1992) Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. Cancer 69:2458PubMedCrossRefGoogle Scholar
  166. Unger JM, Coltman CA, Appelbaum FR et al (2003) African Americans have worse survival in hormone-related cancers. A Southwest Oncology Group Study. Proc Amer Soc Clin Oncol 22:529Google Scholar
  167. Uramoto H, Osaki T, Inoue M et al (1999) Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 35:1462PubMedCrossRefGoogle Scholar
  168. Van Klaveren RJ, Festen J, Otten HJ et al (1993) Prognosis of unsuspected but completely resected N2 non-small cell lung cancer. Ann Thorac Surg 56:300PubMedCrossRefGoogle Scholar
  169. Van Velzen E, Snijder RJ, Brutel de la Rivieire A et al (1997) Lymph node type as a prognostic factor for survival in T2 Nl M0 non-small cell lung carcinoma. Ann Thorac Surg 63:1436PubMedCrossRefGoogle Scholar
  170. Vander Borght T, Pauwels S, Lambotte L et al (1994) Brain tumor imaging with PET and 2-[carbon-11] thymidine. J Nuel Med 35:974Google Scholar
  171. Vansteenkiste J, Stroobants SG, Dupont PJ et al (1999) Prognostic importance of standardized uptake value on (18) F-fluoro-2-deoxyglucose-positron emission tomography scan in non-small cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17:3201PubMedGoogle Scholar
  172. Vesselle H, Schmidt RA, Pugsley JM et al (2000) Lung cancer proliferation correlates with [F-18] fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6:3837PubMedGoogle Scholar
  173. Volm M, Koomagi R (2000) Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer. Oncol Rep 7:95PubMedGoogle Scholar
  174. Volm M, Hahn EW, Mattern J et al (1988) Five-year follow-up study of independent elinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res 48:2923PubMedGoogle Scholar
  175. Volm M, Rittgen W, Drings P (1998) Prognostic value of ERBB-1, VEGF, cyelin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77:663PubMedCrossRefGoogle Scholar
  176. Wang Z, Zhao X (1998) Expression and prognostic relation of cathepsin D in non-small cell lung cancer tissues and lymph nodes. Zhonghua Jie He He Hu Xi Za Zhi 21:164PubMedGoogle Scholar
  177. Werle B, Kraft C, Lah TT et al (2000) Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with non-small cell lung carcinoma. Cancer 89:2282PubMedCrossRefGoogle Scholar
  178. Wertzel H, Siebert H, LangeW et al (1998) Results after surgery in stage I bronchogenic carcinoma. Thorac Cardiovasc Surg 46:365PubMedCrossRefGoogle Scholar
  179. Xu HJ, Quinlan DC, Davidson AG et al (1994) Altered retinoblastoma protein expression and prognosis in early stage non-small cell lung carcinoma. J Natl Cancer Inst 86:695PubMedCrossRefGoogle Scholar
  180. Yano T, Yokoyama H, Inoue T et al (1994) Surgical results and prognostic factors of pathologic N1 disease in non-small cell carcinoma of the lung. Significance of Nl level: Lobar or hilar nodes. J Thorac Cardiovasc Surg 107:1398PubMedGoogle Scholar
  181. Ylisirnio S, Hoyhtya M, Makitaro R et al (2001) Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 7:1633PubMedGoogle Scholar
  182. Yu C, Shun C, Yang P et al (1997) Sialomucin expression is associated with erb B-2 oncoprotein overexpression, early recurrence, and cancer death in non-small cell lung cancer. Am J Respir Crit Care Med 155:1419PubMedCrossRefGoogle Scholar
  183. Zelen M (1973) Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 4:21Google Scholar
  184. Zimmerman PV, Bint MH, Hawson GAT et al (1987) Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet 2:530PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • M. I. Quejada
  • K. S. Albain

There are no affiliations available

Personalised recommendations